Dickie
Arcane
- Joined
- Jul 29, 2011
- Messages
- 4,260
Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game
Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial
BOSTON--(BUSINESS WIRE)--Akili today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for EndeavorRxTM (AKL-T01) as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD). Delivered through a captivating video game experience, EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. See full indication below. Persistent attention issues have a significant impact on the daily lives of millions of people. Attention impairments are a key component of ADHD for many children yet are often overshadowed by more overt symptoms of ADHD.
https://www.businesswire.com/news/home/20200615005739/en/